169 related articles for article (PubMed ID: 38294282)
21. Neutrophil to lymphocyte ratio may predict efficacy of anti-PD-1 inhibitors in advanced EGFR-mutant non-small cell lung cancer: retrospective cohort study.
Chen J; Zheng Q; Zhu S; Qiu D; Wang J
Sci Rep; 2024 Feb; 14(1):4165. PubMed ID: 38378870
[TBL] [Abstract][Full Text] [Related]
22. Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer.
Zheng L; Xiong A; Wang S; Xu J; Shen Y; Zhong R; Lu J; Chu T; Zhang W; Li Y; Zheng X; Han B; Zhong H; Nie W; Zhang X
Front Immunol; 2023; 14():1094378. PubMed ID: 36776882
[TBL] [Abstract][Full Text] [Related]
23. Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab.
Qi WX; Xiang Y; Zhao S; Chen J
Cancer Immunol Immunother; 2021 Nov; 70(11):3199-3206. PubMed ID: 33796915
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Significance of Total Lymphocyte Count, Neutrophil-to-lymphocyte Ratio, and Platelet-to-lymphocyte Ratio in Limited-stage Small-cell Lung Cancer.
Suzuki R; Wei X; Allen PK; Cox JD; Komaki R; Lin SH
Clin Lung Cancer; 2019 Mar; 20(2):117-123. PubMed ID: 30611672
[TBL] [Abstract][Full Text] [Related]
25. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
Zhang N; Jiang J; Tang S; Sun G
Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of PD-L1 Inhibitors plus Chemotherapy versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study.
Qu J; Kalyani FS; Shen Q; Yang G; Cheng T; Liu L; Zhou J; Zhou J
J Oncol; 2022; 2022():3645489. PubMed ID: 36199793
[TBL] [Abstract][Full Text] [Related]
27. Tumor mutational burden adjusted by neutrophil-to-lymphocyte ratio serves as a potential biomarker for atezolizumab-treated patients with extensive stage small cell lung cancer.
Zhang C; Huo Y; Shang X; Zhang T; Tang N; Wang H
Respir Res; 2024 Jun; 25(1):253. PubMed ID: 38902698
[TBL] [Abstract][Full Text] [Related]
28. The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer.
Kang MH; Go SI; Song HN; Lee A; Kim SH; Kang JH; Jeong BK; Kang KM; Ling H; Lee GW
Br J Cancer; 2014 Jul; 111(3):452-60. PubMed ID: 24921916
[TBL] [Abstract][Full Text] [Related]
29. The Relation between Hemogram Parameters and Survival in Extensive-Stage Small Cell Lung Cancer.
Sakin A; Sahin S; Yasar N; Demir C; Arici S; Geredeli C; Cihan S
Oncol Res Treat; 2019; 42(10):506-515. PubMed ID: 31336378
[TBL] [Abstract][Full Text] [Related]
30. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in limited-stage small-cell lung cancer: a meta-analysis.
Zhang S; Wang Y; Cheng Y
Future Oncol; 2023 Jun; 19(18):1303-1314. PubMed ID: 37272402
[No Abstract] [Full Text] [Related]
31. Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer.
Petrova MP; Eneva MI; Arabadjiev JI; Conev NV; Dimitrova EG; Koynov KD; Karanikolova TS; Valev SS; Gencheva RB; Zhbantov GA; Ivanova AI; Sarbianova II; Timcheva CV; Donev IS
Biosci Trends; 2020 Mar; 14(1):48-55. PubMed ID: 32023563
[TBL] [Abstract][Full Text] [Related]
32. The prognostic value of prognostic nutritional index (PNI) and neutrophil to lymphocyte ratio (NLR) for advanced non-small cell lung cancer treated with platinum-based chemotherapeutics.
Wang J; Liu Y; Mi X; Shao M; Liu L
Ann Palliat Med; 2020 May; 9(3):967-978. PubMed ID: 32389020
[TBL] [Abstract][Full Text] [Related]
33. Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer.
Peng J; Zhang L; Wang L; Feng H; Yao D; Meng R; Liu X; Li X; Liu N; Tan B; Huang Z; Li S; Meng X
Radiat Oncol; 2023 Jul; 18(1):111. PubMed ID: 37403111
[TBL] [Abstract][Full Text] [Related]
34. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors.
Peng L; Wang Y; Liu F; Qiu X; Zhang X; Fang C; Qian X; Li Y
Cancer Immunol Immunother; 2020 Sep; 69(9):1813-1822. PubMed ID: 32350592
[TBL] [Abstract][Full Text] [Related]
35. Predictive Value of NLR and PLR in Driver-Gene-Negative Advanced Non-Small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitors: A Single Institutional Cohort Study.
Yuan Q; Xu C; Wang W; Zhang Q
Technol Cancer Res Treat; 2024; 23():15330338241246651. PubMed ID: 38613344
[TBL] [Abstract][Full Text] [Related]
36. Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.
Yao Y; Yuan D; Liu H; Gu X; Song Y
Cancer Immunol Immunother; 2013 Mar; 62(3):471-9. PubMed ID: 22986452
[TBL] [Abstract][Full Text] [Related]
37. PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients.
Zeng R; Liu F; Fang C; Yang J; Luo L; Yue P; Gao B; Dong Y; Xiang Y
Front Immunol; 2021; 12():724443. PubMed ID: 34777341
[TBL] [Abstract][Full Text] [Related]
38. [Impact of the Pretreatment or Posttreatment NLR and PLR on the Response of First Line Chemotherapy and the Outcomes in Patients with Advanced Non-small Cell Lung Cancer].
Yi F; Gu Y; Chen S; Liu Y; Yin W; Zhang Y; Cao B
Zhongguo Fei Ai Za Zhi; 2018 Jun; 21(6):481-492. PubMed ID: 29945708
[TBL] [Abstract][Full Text] [Related]
39. Platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios are associated with the efficacy of immunotherapy in stage III/IV non-small cell lung cancer.
Lu X; Wan J; Shi H
Oncol Lett; 2022 Aug; 24(2):266. PubMed ID: 35782904
[TBL] [Abstract][Full Text] [Related]
40. Neutrophil-to-lymphocyte ratio is superior to platelet-to-lymphocyte ratio as a prognostic predictor in advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.
Guo D; Li M; Chen D; Jing W; Zhu H; Fu L; Kong L; Yue J; Yu J
Future Oncol; 2019 Feb; 15(6):625-635. PubMed ID: 30430864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]